Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed has received a $15 million payment from Ligand Pharmaceuticals under a royalty-based financing agreement, fulfilling a scheduled tranche and bringing Ligand's total investment to $40 million. This funding, alongside a $20 million investment from Medtronic, supports ongoing pivotal clinical trials for Orchestra's AVIM Therapy and Vi…